How a Synthetic LMP-1 Peptide Revealed Mechanism of EBV-Associated Lymphomas

Overview

• Challenge: How does the Epstein-Barr virus (EBV) contribute to the development of Hodgkin’s and non-Hodgkin’s lymphomas?  
• Solution: A synthetic LMP-1 peptide, manufactured by peptides&elephants, enabled the precise in vitro modeling of immune escape via HLA-E signaling.  
• Impact: The findings provide a mechanistic explanation for EBV-driven lymphoma and open avenues for targeted NK cell modulation.
  
  

Background

Epstein-Barr virus (EBV), a lifelong latent herpesvirus, infects over 90% of the global population. While often asymptomatic, its reactivation has been linked to cancer development, especially lymphomas. However, the exact immune mechanisms enabling this transformation remained unclear.

Researchers at the Medical University of Vienna set out to decode how immune escape mechanisms involving natural killer (NK) cells and HLA-E expression might facilitate EBV-driven tumor development.

Key Findings

1. Viral Variants and Immune Escape

In a cohort of 63 lymphoma patients and 192 controls:

• Only EBV strains producing the high-affinity LMP-1 peptide reactivated in patients.
• This variant induced overexpression of HLA-E on infected cells.
• HLA-E was of the high-expressing variant *0103/0103, enhancing NK cell inhibition.

2. Receptor Imbalance

• Inhibitory NKG2A receptors were engaged by HLA-E, silencing NK cells.
• Activating NKG2C receptors were impaired in the lymphoma patients, as it is the case in ~30% of European subjects.
• This double effect allowed EBV-infected tumor cells to evade immune clearance.

3. Reversal via Monoclonal Antibodies

• Blocking NKG2A with monalizumab restored NK cell activity.
• Tumor cells were efficiently cleared in vitro after checkpoint inhibition.